The purpose of the RCT trial is to evaluate whether implantation of drug-eluting stent (DES)
combined with aggressive medical treatment is more efficacious in prevention of composite
event of any stroke and death within 30 days after enrollment and ischemic stroke in the
territories of the responsible artery from 31 days to 1-year after enrollment than optimal
medical treatment for symptomatic intracranial atherosclerotic stenosis.